News | March 19, 2024
Grace expands CDMO capacity by 25% of South Haven facility in Michigan
Additional capacity broadens Grace’s fine chemical capabilities for API production
Additional capacity broadens Grace’s fine chemical capabilities for API production
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Subscribe To Our Newsletter & Stay Updated
